HRP20030559A2 - Stabilized brivudine topical formulations containing metal oxide pigments - Google Patents
Stabilized brivudine topical formulations containing metal oxide pigments Download PDFInfo
- Publication number
- HRP20030559A2 HRP20030559A2 HR20030559A HRP20030559A HRP20030559A2 HR P20030559 A2 HRP20030559 A2 HR P20030559A2 HR 20030559 A HR20030559 A HR 20030559A HR P20030559 A HRP20030559 A HR P20030559A HR P20030559 A2 HRP20030559 A2 HR P20030559A2
- Authority
- HR
- Croatia
- Prior art keywords
- brivudine
- iron oxide
- oxide
- titanium dioxide
- pharmaceutical preparation
- Prior art date
Links
- 229960001169 brivudine Drugs 0.000 title claims description 44
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 title claims description 44
- 239000000049 pigment Substances 0.000 title claims description 15
- 229910044991 metal oxide Inorganic materials 0.000 title claims description 8
- 150000004706 metal oxides Chemical class 0.000 title claims description 8
- 239000012049 topical pharmaceutical composition Substances 0.000 title claims description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 42
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 39
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000006071 cream Substances 0.000 claims description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 239000004408 titanium dioxide Substances 0.000 claims description 19
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 18
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- -1 polyoxyethylene monostearate Polymers 0.000 claims description 13
- 230000000699 topical effect Effects 0.000 claims description 12
- 229940057995 liquid paraffin Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 8
- 239000003871 white petrolatum Substances 0.000 claims description 8
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000011787 zinc oxide Substances 0.000 claims description 7
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000000017 hydrogel Substances 0.000 claims description 6
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019271 petrolatum Nutrition 0.000 claims description 6
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 5
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 5
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 5
- NJESAXZANHETJV-UHFFFAOYSA-N 4-methylsalicylic acid Chemical compound CC1=CC=C(C(O)=O)C(O)=C1 NJESAXZANHETJV-UHFFFAOYSA-N 0.000 claims description 4
- 239000005662 Paraffin oil Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 229940075579 propyl gallate Drugs 0.000 claims description 4
- 235000010388 propyl gallate Nutrition 0.000 claims description 4
- 239000000473 propyl gallate Substances 0.000 claims description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 4
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 claims description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims description 2
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 claims description 2
- 229940083037 simethicone Drugs 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims 9
- 235000013772 propylene glycol Nutrition 0.000 claims 9
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 claims 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 5
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 229940045860 white wax Drugs 0.000 claims 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 3
- 239000001593 sorbitan monooleate Substances 0.000 claims 3
- 229940035049 sorbitan monooleate Drugs 0.000 claims 3
- 235000011069 sorbitan monooleate Nutrition 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004166 Lanolin Substances 0.000 claims 2
- 229960000541 cetyl alcohol Drugs 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 229940039717 lanolin Drugs 0.000 claims 2
- 235000019388 lanolin Nutrition 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 2
- 239000004147 Sorbitan trioleate Substances 0.000 claims 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 235000011037 adipic acid Nutrition 0.000 claims 1
- 150000001279 adipic acids Chemical class 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- 235000019337 sorbitan trioleate Nutrition 0.000 claims 1
- 229960000391 sorbitan trioleate Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 description 10
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 10
- 239000003443 antiviral agent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 208000004898 Herpes Labialis Diseases 0.000 description 4
- 206010067152 Oral herpes Diseases 0.000 description 4
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229960001179 penciclovir Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- 239000004904 UV filter Substances 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000001782 photodegradation Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 230000000176 photostabilization Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01100968 | 2001-01-17 | ||
| PCT/EP2002/000163 WO2002056913A2 (en) | 2001-01-17 | 2002-01-10 | Stabilized brivudine topical formulations containing metal oxide pigments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20030559A2 true HRP20030559A2 (en) | 2005-06-30 |
Family
ID=8176229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030559A HRP20030559A2 (en) | 2001-01-17 | 2003-07-10 | Stabilized brivudine topical formulations containing metal oxide pigments |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20040087602A1 (zh) |
| EP (1) | EP1365772A2 (zh) |
| JP (1) | JP2004519460A (zh) |
| KR (1) | KR20030070109A (zh) |
| CN (1) | CN1236777C (zh) |
| AR (1) | AR035530A1 (zh) |
| AU (1) | AU2002244642B2 (zh) |
| BG (1) | BG107988A (zh) |
| BR (1) | BR0206478A (zh) |
| CA (1) | CA2434743A1 (zh) |
| CZ (1) | CZ20031912A3 (zh) |
| EE (1) | EE200300322A (zh) |
| HR (1) | HRP20030559A2 (zh) |
| HU (1) | HUP0302741A3 (zh) |
| IL (1) | IL156933A0 (zh) |
| MA (1) | MA26266A1 (zh) |
| MX (1) | MXPA03006307A (zh) |
| MY (1) | MY136633A (zh) |
| NO (1) | NO20033206D0 (zh) |
| PE (1) | PE20020818A1 (zh) |
| PL (1) | PL365741A1 (zh) |
| RU (1) | RU2280453C2 (zh) |
| SK (1) | SK8992003A3 (zh) |
| TN (1) | TNSN03036A1 (zh) |
| UA (1) | UA80673C2 (zh) |
| WO (1) | WO2002056913A2 (zh) |
| YU (1) | YU57103A (zh) |
| ZA (1) | ZA200305437B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005046769A1 (de) * | 2005-09-29 | 2007-04-05 | Berlin-Chemie Ag | Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus) |
| FR2936706B1 (fr) * | 2008-10-08 | 2010-12-17 | Oreal | Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane |
| CN106344533A (zh) * | 2009-01-29 | 2017-01-25 | 大日本住友制药株式会社 | 具有内核的口腔崩解片剂 |
| EP3272346A4 (en) * | 2015-03-19 | 2018-08-01 | Daiichi Sankyo Company, Limited | Solid preparation containing colorant |
| CN104988791A (zh) * | 2015-06-25 | 2015-10-21 | 广东义晟实业有限公司 | 一种抗病毒添加剂及添加该添加剂的胶水和uv漆 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0072137A1 (en) * | 1981-08-01 | 1983-02-16 | Beecham Group Plc | Antiviral deoxyuridine compounds |
| HU196038B (en) * | 1987-08-07 | 1988-09-28 | Mta Koezponti Kemiai Kutato In | Process for producing antiherpetic pharmaceutics for external use, containing 5-isopropyl-2'-beta-deoxy-uridine |
| DE4122337A1 (de) * | 1991-07-05 | 1993-01-14 | Cedona Pharm Bv | Pharmazeutische zubereitung |
| FR2737118B1 (fr) * | 1995-07-28 | 1997-09-05 | Oreal | Composition dermatologique ou pharmaceutique, procede de preparation et utilisation |
| GB9521454D0 (en) * | 1995-10-19 | 1995-12-20 | Kappa Pharmaceuticals Ltd | Compositions for the treatment of conditions caused by herpes virus |
| US6558710B1 (en) * | 1999-06-14 | 2003-05-06 | Helen Rebecca Godfrey | Topical zinc compositions and methods of use |
| DE10162593A1 (de) * | 2001-12-19 | 2003-07-03 | Menarini Ricerche Spa | Stabilisierte topische Brivudin-Formulierungen |
-
2001
- 2001-12-24 MY MYPI20015863A patent/MY136633A/en unknown
-
2002
- 2002-01-10 BR BR0206478-2A patent/BR0206478A/pt not_active IP Right Cessation
- 2002-01-10 MX MXPA03006307A patent/MXPA03006307A/es not_active Application Discontinuation
- 2002-01-10 CN CNB028037448A patent/CN1236777C/zh not_active Expired - Fee Related
- 2002-01-10 CZ CZ20031912A patent/CZ20031912A3/cs unknown
- 2002-01-10 CA CA002434743A patent/CA2434743A1/en not_active Abandoned
- 2002-01-10 WO PCT/EP2002/000163 patent/WO2002056913A2/en not_active Application Discontinuation
- 2002-01-10 IL IL15693302A patent/IL156933A0/xx unknown
- 2002-01-10 JP JP2002557420A patent/JP2004519460A/ja active Pending
- 2002-01-10 SK SK899-2003A patent/SK8992003A3/sk not_active Application Discontinuation
- 2002-01-10 EE EEP200300322A patent/EE200300322A/xx unknown
- 2002-01-10 KR KR10-2003-7009444A patent/KR20030070109A/ko not_active Application Discontinuation
- 2002-01-10 HU HU0302741A patent/HUP0302741A3/hu unknown
- 2002-01-10 AU AU2002244642A patent/AU2002244642B2/en not_active Ceased
- 2002-01-10 EP EP02712810A patent/EP1365772A2/en not_active Withdrawn
- 2002-01-10 PL PL02365741A patent/PL365741A1/xx not_active Application Discontinuation
- 2002-01-10 RU RU2003121639/15A patent/RU2280453C2/ru not_active IP Right Cessation
- 2002-01-10 US US10/466,305 patent/US20040087602A1/en not_active Abandoned
- 2002-01-10 YU YU57103A patent/YU57103A/sh unknown
- 2002-01-16 PE PE2002000027A patent/PE20020818A1/es not_active Application Discontinuation
- 2002-01-16 AR ARP020100151A patent/AR035530A1/es not_active Application Discontinuation
- 2002-10-01 UA UA2003076388A patent/UA80673C2/uk unknown
-
2003
- 2003-06-30 MA MA27219A patent/MA26266A1/fr unknown
- 2003-07-08 TN TNPCT/EP2002/000163A patent/TNSN03036A1/fr unknown
- 2003-07-10 HR HR20030559A patent/HRP20030559A2/hr not_active Application Discontinuation
- 2003-07-10 BG BG107988A patent/BG107988A/bg unknown
- 2003-07-15 NO NO20033206A patent/NO20033206D0/no not_active Application Discontinuation
- 2003-07-15 ZA ZA200305437A patent/ZA200305437B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20040087602A1 (en) | 2004-05-06 |
| EP1365772A2 (en) | 2003-12-03 |
| RU2003121639A (ru) | 2005-02-10 |
| NO20033206L (no) | 2003-07-15 |
| CN1486185A (zh) | 2004-03-31 |
| AU2002244642B2 (en) | 2005-12-15 |
| PE20020818A1 (es) | 2002-10-21 |
| HUP0302741A2 (hu) | 2003-11-28 |
| WO2002056913A2 (en) | 2002-07-25 |
| TNSN03036A1 (en) | 2005-04-08 |
| MY136633A (en) | 2008-11-28 |
| NO20033206D0 (no) | 2003-07-15 |
| CA2434743A1 (en) | 2002-07-25 |
| EE200300322A (et) | 2003-10-15 |
| AR035530A1 (es) | 2004-06-02 |
| PL365741A1 (en) | 2005-01-10 |
| BR0206478A (pt) | 2003-12-30 |
| UA80673C2 (en) | 2007-10-25 |
| BG107988A (bg) | 2004-09-30 |
| CN1236777C (zh) | 2006-01-18 |
| HUP0302741A3 (en) | 2007-06-28 |
| WO2002056913A3 (en) | 2002-11-07 |
| CZ20031912A3 (cs) | 2004-01-14 |
| IL156933A0 (en) | 2004-02-08 |
| SK8992003A3 (en) | 2003-11-04 |
| YU57103A (sh) | 2006-08-17 |
| RU2280453C2 (ru) | 2006-07-27 |
| MXPA03006307A (es) | 2003-09-16 |
| MA26266A1 (fr) | 2004-09-01 |
| KR20030070109A (ko) | 2003-08-27 |
| JP2004519460A (ja) | 2004-07-02 |
| ZA200305437B (en) | 2004-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3661707B2 (ja) | 皮膚外用剤 | |
| WO2004016238A1 (ja) | 老化防止用組成物 | |
| SI9300469A (en) | Antivirally active pharmaceutical oil-in-water emulsion containing 9-((2-hydroxyethoxy)methyl)guanine (acyclovir) or salt or ester thereof | |
| HRP20030559A2 (en) | Stabilized brivudine topical formulations containing metal oxide pigments | |
| JPH08175960A (ja) | シワ予防用化粧料 | |
| JPH05124925A (ja) | メラニン生成抑制外用剤 | |
| JPH0545569B2 (zh) | ||
| WO1999027966A1 (fr) | Composition de preparation liquide a base de minoxidil | |
| JPS61215318A (ja) | 皮膚外用剤 | |
| JP2007176934A (ja) | 血小板活性化因子アセチルヒドロラーゼ機能調整剤 | |
| JP2003176217A (ja) | 皮膚外用剤 | |
| WO2020004194A1 (ja) | 外用組成物 | |
| AU2002244642A1 (en) | Stabilized brivudine topical formulations containing metal oxide pigments | |
| KR101425902B1 (ko) | 하이드록삼산 유도체를 포함하는 피부 미백용 화장료 조성물 | |
| JPH05124924A (ja) | メラニン生成抑制外用剤 | |
| JPH05124923A (ja) | メラニン生成抑制外用剤 | |
| JP2006516613A (ja) | 単純疱疹の予防的治療のための調合物 | |
| JPH05124947A (ja) | メラニン生成抑制外用剤 | |
| KR101438376B1 (ko) | ｐＨ 조절을 통해 안정화된 프룩토오스 1,6-디포스페이트 화합물을 함유하는 피부 외용제 조성물 | |
| JP6727781B2 (ja) | 乳化組成物 | |
| HU196038B (en) | Process for producing antiherpetic pharmaceutics for external use, containing 5-isopropyl-2'-beta-deoxy-uridine | |
| JPH05132422A (ja) | メラニン生成抑制外用剤 | |
| JPH05124922A (ja) | メラニン生成抑制外用剤 | |
| JPH05124948A (ja) | メラニン生成抑制外用剤 | |
| JP5768114B2 (ja) | エージング対応用の皮膚外用剤の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20061229 Year of fee payment: 6 |
|
| ODBI | Application refused |